Therapeutic targeting of lysosome-triggered inflammatory channels in nasal and upper-airway allergic conditions - Top-Institutions - MDSpire

Therapeutic targeting of lysosome-triggered inflammatory channels in nasal and upper-airway allergic conditions

  • By

  • Haoran Yu

  • Yujin Zheng

  • Daquan Wu

  • Lei Zhou

  • Kanglun Jiang

  • Kaisai Tian

  • Na Shen

  • May 26, 2026

Share

Top Institutions in Otolaryngology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts Eye and Ear, Harvard Medical School
    Massachusetts Eye and Ear, Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Otolaryngology
    • Allergy and Immunology

  • #2

    Northwestern University Feinberg School of Medicine
    Northwestern University Feinberg School of Medicine

    Chicago, Illinois

    Key Differentiators

    • Otolaryngology
    • Allergy and Immunology

  • #3

    American University of Beirut Medical Center
    American University of Beirut Medical Center

    Beirut, Lebanon

    Key Differentiators

    • Otolaryngology

  • #4

    Queens Hospital
    Queens Hospital

    New York, New York

    Key Differentiators

    • Otolaryngology

  • #5

    The Ohio State University College of Optometry
    The Ohio State University College of Optometry

    Columbus, Ohio

    Key Differentiators

    • Optometry

Original Source(s)

Therapeutic targeting of lysosome-triggered inflammatory channels in nasal and upper-airway allergic conditions

  • by Haoran Yu, Yujin Zheng, Daquan Wu, Lei Zhou, Kanglun Jiang, Kaisai Tian, Na Shen

  • May 26, 2026

Related Content

Can Lower Music Levels Preserve Workout Intensity?

Despite preserved exertion perceptions, researchers report limited hearing protection use in group fitness classes.

The Bill Nobody's Discussing in the Exam Room

Head and neck cancer costs are crushing patients — yet cost discussions remain uncommon in clinical care.

Reduced-Dose Radiation Shows Durable Control

Single-arm cohort findings contrast with interim results from NRG-HN005, underscoring ongoing uncertainty around treatment deintensification.